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Abstract 
Purpose: To explore the effect of a combination of ulinastatin and continuous renal replacement 
therapy (CRRT) for the treatment of severe sepsis with acute kidney injury (SAKI).  
Methods: Clinical data for 106 patients diagnosed with SAKI from April 2013 to May 2015 in the 
intensive care unit (ICU) of Affiliated Hospital of Zhengzhou University, Zhengzhou, China, were 
collected and randomly assigned into two groups: treatment and control groups. The general 
information on the two groups were comparable. All the patients received a comprehensive treatment 
program which included fluid resuscitation, antibiotics, nutritional support and CRRT. The patients in 
treatment group also received intravenous injection of 300 thousand units/10 mL ulinastatin thrice daily 
for 5 days. Serum levels of inflammatory cytokines, oxidative stress level, kidney and blood coagulation 
functions were assayed before and after treatment, using standard methodologies. In addition, adverse 
reactions and 28-day mortality were recorded.  
Results: Levels of interleukin-6 (IL-6), tumor necrosis factor α (TNFα), serum C-reactive protein (CRP), 
procalcitonin (PCT), malondialdehyde (MDA), cystatin, blood urea nitrogen (BUN), prothrombin time 
(PT), activated partial thromboplastin time (APTT), serum creatinine (SCr) and urinary kidney injury 
molecule-1 (Kim-1) in the treatment group were significantly lower than those in the control group after 
ulinastatin treatment (p < 0.05). However, superoxide dismutase (SOD), fibrinogen (Fib) and total 
antioxidant capacity (T-AOC) in the treatment group were significantly higher in the control group after 
treatment (p < 0.05). No serious adverse drug reactions were seen in the two groups. In addition, there 
were no significant differences in 28-day mortality between the two groups.  
Conclusion: These results suggest that ulinastatin combined with CRRT effectively decreases serum 
levels of inflammation in SAKI patients through a mechanism involving improvement of antioxidant 
capacity, reduction of oxidative stress, and enhancement of renal and coagulation functions. 
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Sepsis is a common complication of wounds, 
burns, infection and other severe conditions in 
clinics. Sepsis may lead to multiple organ 
dysfunction syndromes (MODS), a crucial area in 
intensive medicine. Studies show that there are 
about 18 million cases of new sepsis patients 
each year, accounting for 0.3 % of the total 
population, and growing at a rate of 1.5 %  per 
year [1-4]. Although the treatment program for 
sepsis is regularly optimized, there is always high 
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mortality rate in these patients. Acute kidney 
injury (AKI) is one of the common complications 
of sepsis. Indeed about 40% of sepsis eventually 
develops into sepsis-mediated acute kidney 
injury (SAKI). Mortality from SAKI is up to 70 %, 
which is about twice the population of sepsis 
patients without AKI [5,6]. 
 
Continuous renal replacement therapy (CRRT) 
refers to blood purification therapy involving slow 
but continuous water clearance and solute 
exchange through diffusion, convection and 
adsorption. This has been widely used for clinical 
treatment of sepsis, severe acute pancreatitis 
and intractable heart failure [7,8]. In a 
retrospective study, Zhiping et al found that 
CRRT improved negative fluid balance in SAKI 
patients, reversed poor prognosis, enhanced 
recovery of renal function and reduced long-term 
mortality [9].  
 
Ulinastatin, a urinary tripsin inhibitor, improves 
microcirculation and tissue perfusion, relieves 
tissue and organ damage, regulates 
inflammatory cytokines and controls imbalances 
in inflammatory response, all of which contribute 
to efficacy and safety of treatment of sepsis, 
severe pancreatitis and acute coronary 
syndrome [10].  
 
In this study, the clinical effects of treatment of 





Patients and study design 
 
The clinic data for 153 patients diagnosed with 
sepsis from April 2013 to May2015 in the 
Intensive Care Unit of The Second Affiliated 
Hospital of Zhengzhou University were collected. 
The recruitment criteria were (1) Age > 18 years; 
(2) patient must meet AKI diagnostic criteria as 
defined by the 2001 Washington International 
Conference (3) diagnosis of AKI must be 
consistent with AKI diagnostic criteria by the 
Acute Kidney Injury Collaboration Network in 
2005 and (4) expected survival time of > 1. The 
exclusion criteria were (1) medical history of any 
pre-existing chronic kidney disease such as 
glomerulonephritis and interstitial nephritis; (2) 
pre-existing kidney surgical history; (3) co-
existing autoimmune disease, immunodeficiency 
disease or blood disorders; (4) patients who took 
glucocorticoids, immune suppressants and 
anticoagulants within the previous three months; 
(5) evidence of presence of CRRT or contra-
indications for ulinastatin application and (6) 
patients with severe liver and kidney dysfunction, 
and heart failure. Altogether, 106 patients met 
the required recruitment standards. These 
patients were assigned to observation and 
control groups using random list method. .This 
research was approved by the Ethical Committee 
of The Second Affiliated Hospital of Zhengzhou 
University (approval no.2016-02-01) and the 
studies were carried out according to Declaration 
of Helsinki promulgated in 1964 as amended in 




All patients were treated for primary diseases, 
and given fluid resuscitation and antibiotics. 
Other procedures used included monitoring of 
vital signs, nutritional support, mechanical 
ventilation, correction of water and electrolyte 
acid-base balance disorders, prevention of heart 
failure, and control of blood sugar and blood 
pressure. On the basis of the above, treatment 
for control group was CRRT, wherein the blood 
filter was Prismaflex (Swedish Campbell Medical 
Products Co., Ltd.), the colander was AN69-
M100 matched with the blood filter; vascular 
access was large-diameter double lumen 
intravenous catheter for femoral vein indwelling 
for blood purification with mode of continuous 
veno - venous hemofiltration (CVVH, a mode of 
CRRT), the replacement fluid formulation was 
provided by Nanjing Military Region General 
hospital, replacement fluid flow rate was 35 
ml•kg-1•h-1 and blood flow rate was 200ml/min, 
lasting 12h ~ 24 h each time. In the absence of 
contra-indications, conventional low molecular 
weight heparin was applied continuously for 5 
days. The observation group received 
intravenous injection of 300,000 U of ulinastatin 
(Guangdong Techpool Pharmaceutical Co., Ltd., 
Zhunzi H20040506, China) continuously 3 times 
a day for 5 days. 
 
Evaluation of serum parameters 
 
Prior to treatment and 7 days after treatment, 
serum CRP, PCT, TNF-α and IL-6 levels were 
assayed by immune nephelometry, electro-
chemical luminescence and enzyme-linked 
immunosorbent assay (ELISA) kits, as 
appropriate. The kits were purchased from 
Roche Co., Ltd., Germany. Other parameters 
that were assayed before and after 7-day 
treatment were BUN, SCr, urinary Kim-1 and 
cystatin (CysC). The last two parameters were 
measured by ELISA assay (Shanghai Haibo 
Institute Co., Ltd, Shanghai China). Prothrombin 
time (PT), APTT, Fib, SOD, T-AOC and MDA 
levels were determined with appropriate kits 
using OLYMPUS Automatic Biochemistry 
Instrument (Nanjing Jiancheng Bioengineering 
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Institute, Nanjing, China). Mortality and adverse 





Experimental data were analyzed statistically 
with SPSS 20.0 software. Measurement data 
were expressed as mean ± standard deviation 
(SD). Comparison between the two groups was 
conducted with analysis of variance (ANOVA). 
Enumeration data were expressed as 
percentage, and compared with Chi-square test. 




Characteristics of participants 
 
Each group had 53 patients. Four patients in 
treatment group withdrew from the study within 7 
days due to transfers and other factors, while 6 
individuals withdrew from control group. Thus the 
actual treatment cases were 49 in the treatment 
group and 47 in control.  
 
There was no statistically significant differences 
in gender, age, primary tumor site, pathogens, 
acute physiology and chronic health evaluation 
(APACE II rates) and Marshall score comparison 




Before treatment, there were no significant 
differences in levels of serum PCT, CRP, IL-6 
and TNF-α between the two groups (p > 0.05). 
However, after treatment with ulinastatin, serum 
levels of PCT, CRP, IL-6 and TNF-α decreased 
significantly when compared with values before 
the treatment (p< 0.05). Importantly, after 
treatment, levels of serum PCT, CRP, IL-6 and 
TNF-α in the observation group significantly 
decreased relative to corresponding levels in 




Before treatment, there were no significant 
differences in levels of serum CysC, BUN, SCr 
and urinary Kim-1 between patients in the two 
groups. However, after treatment, serum CysC, 
BUN, SCr and urinary Kim-1 levels were 
significantly increased when compared with 
corresponding values before treatment, although 
the post-treatment levels in the observation 
group decreased more than in the control group 
(p < 0.05, Table 3). 
 
Effect on coagulation function 
 
No significant differences existed in the levels of 
PT, APTT and serum Fib in patients from the two 
groups prior to treatment. 
Table 1: Comparison of baseline characteristics of the two groups 
 
Group N Age Gender (M / F) 
Primary lesion site Pathogenic bacteria APACEⅡ Marshall L A B O GN GP MI 
Observation 49 56.7±12.5 35/14 22 14 7 6 34 8 7 22.3±4.5 10.1±2.5 
Control 47 59.3±11.6 30/17 25 9 10 3 37 6 3 21.7±3.9 10.6±2.1 
t / χ2  1.07 0.63 2.77 1.92 0.70 1.07 
P  0.29 0.43 0.43 0.38 0.48 0.29 
M = male; F = female; L= lung; A= abdominal cavity; B = blood; O = others; GN = gram negative bacteria; GP = 
Gram positive bacteria; MI= mixed infection 
 
Table 2: Levels of serum inflammatory cytokines in the two groups before and after treatment with ulinastatin 
 
Group PCT (ng/mL) CRP (mg/L) TNF-α (ng/L) IL-6 (ng/L) Before After Before After Before After Before After 
Treatment 5.5±2.2 1.6±0.9*# 75.5±21.3 27.4±13.3*# 177.5±25.9 107.3±20.7*# 213.2±27.7 127.5±24.7*#) 
Control 5.7±2.2 2.7±0.8* 73.6±18.8 48.7±14.6* 183.3±23.8 138.4±26.8* 209.3±31.65 159.7±28.2* 
t 0.32 6.24 0.48 7.57 1.15 6.42 0.70 6.03 
P 0.75 0.00 0.63 0.00 0.25 0.00 0.49 0.00 
  *p <0.05 compared with pre- treatment; #p < 0.05 compared with control group 
 
Table 3: Levels of renal function parameters in the two groups before and after treatment with ulinastatin 
 
Group Urinary Kim-1(μg/L) Cys C (mg/L) BUN (mmol/L) SCr(μmol/L) Before After Before After Before After Before After 
Treatment 4.75±0.38 5.2   3.32±0.36 5.28±0.47*# 11.32±3.34 14.53±3.15*# 137.37±22.54 238.47±25.45*# 
Control 4.68±0.40 5.72±0.35 3.40±0.28 6.11±0.42* 10.87±3.58 16.42±2.77* 133.82±20.73 186.62±27.83* 
t 0.89 5.80 1.22 9.21 0.64 3.15 0.81 9.87 
P 0.38 0.00 0.22 0.00 0.52 0.00 0.42 0.00 
*p <0.05 compared with pre- treatment; #p < 0.05 compared with control group 
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However, after treatment, PT and APTT levels 
were significantly reduced relative to values 
before treatment, while serum Fib level became 
significantly elevated (p < 0.05). After treatment, 
PT and APTT levels in the observation group 
were significantly lower than corresponding 
values in the control group (p < 0.05), while 
serum Fib level was significantly higher (p < 
0.05, Table 4). 
 
Oxidative stress  
 
Prior to treatment, there were no significant 
differences in serum SOD, AOC and MDA 
profiles between patients in the two groups, but 
after treatment, SOD and AOC increased 
significantly, while MDA was significantly 
reduced (p < 0.05).  
 
In addition, SOD and AOC levels in observation 
group were significantly higher than 
corresponding values in the control group, while 
serum MDA was significantly reduced (p< 0.05, 
Table 5). 
 
Mortality and adverse reactions 
 
During the ulinastatin treatment, there were no 
serious adverse drug reactions in either group. In 
the observation group, one patient had rashes, 
another one had mild drop in blood pressure 
while one patient experienced paroxysmal atrial 
fibrillation. Two cases of mild nausea were seen 
in the control group. These adverse conditions 
were relieved after symptomatic treatment. 
During the 28-day treatment, there were 13 dead 
cases in the observation group (mortality rate of 
17.8 %), while 17 cases died in the control group 
(mortality rate of 20.2 %), indicating no significant 
difference in mortality in the two groups (χ2 = 




Mechanisms involved in sepsis-mediated AKI are 
complicated. It is thought that toxins released by 
infections activate inflammatory cells to induce 
large release of inflammatory mediators such as 
IL-6, TNF-α. 
 
These activate Toll-like 4 receptor, and form 
inflammatory reaction cascade leading to 
pathophysiological changes in renal vascular 
endothelial cells and renal parenchymal cells, 
and eventually kidney damage [12]. Sepsis 
patients have changes in their neuroendocrine 
system such as activation of sympathetic 
nervous system, release of vasopressin, and 
activation of renin - angiotensin - aldosterone 
system. These changes can result in decrease in 
renal blood flow, renal tubular epithelial cell 
necrosis and decline in renal function [13]. 
 
Release of large number of inflammatory factors 
can damage the endothelial cells of patients with 
sepsis, activate the coagulation system to a 
hyper-coagulable state, induce formation of renal 
micro vascular thrombosis and affect renal 
perfusion [14]. In addition, endotoxemia 
increases reactive oxygen species (ROS) 
generated by mitochondrial respiratory chain and 
decreases enzyme activities in tubular epithelial 
cell. These will induce retention of large amounts 
of oxygen free radicals in the body, and then 
accelerate lipid peroxidation, membrane 
damage, apoptosis and renal tubular epithelial 
damage and decline in kidney function [15]. 
 
 
Table 4: Coagulation function of the two groups before and after treatment 
 
Group 
PT (s) APTT (s) Fib (g/L) 
Before After Before After Before After 
Treatment 23.15±1.52 14.42±1.50*# 47.87±4.12 41.28±4.37*# 1.77±0.52 2.93±0.63*# 
Control 22.82±1.35 16.35±1.47* 48.10±4.25 44.57±4.56* 1.82±0.59 2.12±0.57* 
T 1.13 6.43 0.27 3.65 0.45 6.67 
P 0.26 0.00 0.79 0.00 0.66 0.00 
*p <0.05 compared with pre- treatment; #p < 0.05 compared with control group 
 
       Table 5: Oxidative stress status of the two groups before and after treatment with ulinastatin 
 
Group SOD (U/mL) T-AOC (U/mL) MDA (nmol/mL) Before After Before After Before After 
Observation 66.36±12.35 86.46±11.73*# 5.35±1.12 7.65±1.20*# 14.35±1.10 10.54±1.17*# 
Control 67.42±10.68 75.34±12.55* 5.42±1.23 6.33±1.05* 14.42±1.13 12.20±1.08* 
t 0.45 4.76 0.29 5.79 0.31 7..29 
P 0.65 0.00 0.77 0.00 0.76 0.00 
           *p <0.05 compared with pre- treatment; #p < 0.05 compared with control group 
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The key to SAKI treatment is to remove 
endotoxins in patients, block inflammation, 
reduce oxidative stress levels, improve blood 
coagulation, and gradually enhance renal 
function. CRRT can maintain stable dynamics of 
blood flow in patients with sepsis, remove 
metabolic waste, endotoxins and inflammatory 
cytokines and correct water and electrolyte acid-
base disorders. In a prospective study, Xu et al 
found that early CRRT greatly improved 28-day 
survival in patients with SAKI [16]. Dai et al also 
confirmed that CRRT can significantly improve 
the prognosis of patients with SAKI, and shorten 
organ support time and length of stay in ICU [17].  
 
Ulinastatin, as a broad-spectrum proteinase 
inhibitor, inhibits all types of hydrolytic enzymes, 
stabilize lysosomal membrane, reduce oxygen 
free radicals, suppress the release of 
inflammatory mediators, and also mitigate 
damage to heart, kidney, brain, lung and other 
organs. Wu et al found that ulinastatin can 
effectively reduce the expression of regulatory T 
cells (Treg) and helper T- cells17 (Th17) in 
patients with severe sepsis, reverse imbalance in 
Treg/Th 17 ratio, down-regulate IL-17, IL-6, and 
IL-10 levels; increase monocyte human 
leukocyte DR antigen (HLA-DR) and improve 
cellular immunity, all of which are expected to 
improve the prognosis of patients with severe 
sepsis [18]. 
 
This study showed that serum PCT, CRP, IL-6 
and TNF-α levels in the observation group were 
significantly lower than those of the control group 
after treatment with ulinastatin, suggesting that 
the drug can control inflammatory responses by 
reducing levels of inflammatory factors in 
patients with sepsis, thereby relieving 
inflammatory damage to tissues and organs. 
Superoxide Dismutase (SOD) is major 
antioxidant enzyme for scavenging oxygen free 
radicals in patients with sepsis, and T-AOC is a 
comprehensive indicator reflecting the overall 
level of enzymatic and non-enzymatic 
antioxidants. 
 
MDA is one of the main products of oxygen free 
radical-induced lipid peroxidation in biological 
membranes; it indicates indirectly the levels of 
oxygen free radicals and oxidative damage [19]. 
This study showed that serum SOD and AOC 
levels in the observation group were more 
remarkably increased than in control after 
treatment, while serum MDA level were 
significantly lower. This suggests that ulinastatin 
can effectively reduce oxygen free radical levels 
in patients with SAKI and elevate antioxidant 
capacity to reduce oxidative stress damage. The 
large number of endotoxins and inflammatory 
mediators in patients with SAKI can result in 
dysfunction of the endogenous and exogenous 
coagulation system, accompanied by declines in 
coagulation factors and platelets. Thus, PT and 
APTT in SAKI patients were increased 
significantly, while Fib level declined. The results 
of this study show PT and APTT in the 
observation group patients were significantly 
lower than in the control group after treatment, 
while serum Fib levels were significantly higher, 
indicating that ulinastatin can effectively improve 
blood coagulation in patients with SAKI. 
However, the specific regulatory mechanism 
involved in this ulinastatin effect remains to be 
further explored. 
 
Kim-1 is a type I trans-membrane protein with 
high tissue-specificity, which has good sensitivity 
and specificity in the diagnosis of AKI [20]. CysC 
is a cysteine protease inhibitor which reflects 
changes in glomerular filtration rate [21]. The 
results of this study show that serum CysC, BUN, 
SCr and urinary Kim-1 in the observation group 
were significantly lower than in the control group 
after treatment, indicating that ulinastatin 
combined with CRRT can prevent continued 
deterioration of renal function in patients with 
SAKI. In addition, this study showed there were 
no treatment-related serious adverse reactions, 
suggesting that ulinastatin did not increase 
metabolic burden of SAKI patients or impose 
additional side effects.  
 
Limitations of the study 
 
There was no long term follow-up on the SAKI 
patients. There is still a need for a randomized 
controlled study with a larger sample size and 




Ulinastatin combined with CRRT effectively 
controls serum levels of inflammation factors in 
SAKI patients via improvement in antioxidant 
capacity, reduction in oxidative stress, as well as 
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